3 results match your criteria: "Cancer Center of the Carolinas[Affiliation]"
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Ann Oncol
September 2011
Department of Hematology and Oncology, The West Clinic, Memphis, USA.
Article Synopsis
- A phase II study compared the effectiveness (objective response rate or ORR) of two treatment regimens, motesanib and bevacizumab, combined with chemotherapy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).
- Patients were randomly assigned to one of three treatment groups, receiving either motesanib (in two different dosing regimens) or bevacizumab, with effectiveness measured by ORR and other outcomes such as progression-free survival (PFS) and overall survival (OS).
- Results indicated that the ORR was highest with bevacizumab (37%), and while the toxicity was increased in the motesanib groups, it was considered manageable, leading to further investigation of motesan
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
Clin Cancer Res
April 2004
Cancer Center of the Carolinas, Greenville, South Carolina, USA.
Purpose: Expansion and activation of natural killer (NK) cells with interleukin-2 (IL-2) may enhance antibody-dependent cellular cytotoxicity (ADCC), an important mechanism of rituximab activity. Two parallel Phase I studies evaluated combination therapy with rituximab and IL-2 in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Experimental Design: Thirty-four patients with advanced NHL received rituximab (375 mg/m(2) i.
Gemcitabine hydrochloride.
Clin J Oncol Nurs
May 2002
Cancer Center of the Carolinas, Greenville, SC, USA.